Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Estetra Srl has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This application is assigned to 1 distinct examiner and 1 distinct art unit. The company current patent prosecution is limited to this single administrative path, which indicates a concentrated focus on a specific technical disclosure within the pharmaceutical sector.
ISMAIL, REHANA is the busiest examiner, overseeing 1 pending office action. With 1 distinct examiner and 1 distinct art unit, the company current strategy is focused on a single point of review. The outcome of this specific office action will determine the immediate progress of the company biotechnological intellectual property. The presence of 1 pending office action suggests a streamlined prosecution phase. Practitioners must tailor their arguments to the specific technical standards of this single art unit to advance the application toward allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ISMAIL, REHANA | 1 | 76.2% | +34.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837118 | CONTRACEPTIVE METHODS WITH SCHEDULED BLEEDING EFFECTS | ISMAIL, REHANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837118 | CONTRACEPTIVE METHODS WITH SCHEDULED BLEEDING EFFECTS | ISMAIL, REHANA | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837118 | CONTRACEPTIVE METHODS WITH SCHEDULED BLEEDING EFFECTS | ISMAIL, REHANA | 1625 | §102§112 | Non-Final OA | — | Pending | Aug 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEstetra Srl has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Rehana Ismail has the most, with 1 of Estetra Srl's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.